MAP2K1 and cancer: Conditioned media from docetaxel-treated stromal cells increased ERK-activation in TSOs and selumetinib, an MEK1/2 inhibitor, prevented chemotherapy-induced dormancy escape in vitro and in vivo, reducing cancer cell proliferation without impacting stromal cells.